A Genmab acquisition focuses on head and neck cancer

Also: The cancer cases reported out of missile bases around the Northwest

September 30, 2025 Check out STAT+

Sponsored By

Mario Tama/Getty Images STAT+ | Genmab to buy Merus in $8B deal The acquisition is centered on petosemtamab, a promising treatment for head and neck cancer that is in Phase 3 trials. By Andrew Joseph STAT+ | Doctors face off with Cigna over new policy that may cut reimbursements This week in health care business news: Doctors are at odds with Cigna over a new billing policy, Medicare Advantage audits face legal setback. By STAT Staff and Tara Bannow STAT+ | GSK CEO Walmsley to step down, be succeeded by company's commercial lead Walmsley has led GSK since 2017, focusing the company on innovative medicines. Miels has been running commercial operations. By Andrew Joseph John Moore/Getty Images STAT+ | Patients set to lose hospital care at home if government funding isn't extended CMS officials warn hospitals that if funding ends for a Medicare hospital-at-home program, 'all inpatients must be discharged or returned to the hospital.' By John Wilkerson and Mario Aguilar

More around STAT

---

In case you missed it Nuclear missile workers are contracting cancer. They blame the bases, North Dakota Monitor To treat prostate cancer, there are more options than ever, New York Times NIH pulled off a "near miracle." Scientists say there's still a problem. Hundreds of grants deemed excellent by peer review are being left on the table, leaving strong research on cancer unfunded, Washington Post

---

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Cancer Briefing? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser